Form 4: NKGen Biotech Director Awarded Stock Options

Kathleen D. Scott, a director at NKGen Biotech, was granted stock options for 800,000 shares on December 6, 2024, under the company's 2023 Equity Incentive Plan.

Summary

• Kathleen D. Scott, a director at NKGen Biotech, received stock options for a total of 800,000 shares on December 6, 2024.
• The options were granted under the company's 2023 Equity Incentive Plan.
• 300,000 of the options have an exercise price of $1.62 per share.
• 500,000 of the options have an exercise price of $0.438 per share.
• The 300,000 options vest with 40% immediately and the remainder in 20 equal monthly installments starting January 6, 2025.
• The 500,000 options vest in 36 equal monthly installments starting January 6, 2025.
• All vesting is contingent on the director's continued service with the company.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate practice of granting stock options to a director, which is generally viewed positively as it aligns interests. There are no indications of negative sentiment.

Positives

• The granting of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Risks

• The value of the options is dependent on the future performance of the company's stock price.
• The director must remain with the company to fully vest the options.

Future Outlook

The vesting of the options is contingent on the director's continued service with the company, suggesting a focus on long-term engagement.

Industry Context

Stock option grants are a common practice in the biotech industry to incentivize and retain key personnel, particularly directors.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedules described are typical, with a mix of immediate and time-based vesting to align director interests with long-term company performance.
• The exercise prices are likely based on the company's stock price at the time of the grant, which is a common practice.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the director to work towards the company's success.
• The director is incentivized to remain with the company to fully vest the options.

Key Dates

Keywords

stock options, equity incentive plan, director, vesting, NKGen Biotech, compensation